Payment overview · 2025
General Payments
$1,250.38
38 reported records · 11 companies
Healthcare provider profile · identity verified
Leonid Bukhman, M.D
Allopathic & Osteopathic Physicians|Internal Medicine · NEW YORK, NY · NPI 1144334699
Verified facts
What the public records show
CMS Open Payments records show Leonid Bukhman, M.D received $1,250.38 in general payments during 2025 across 38 reported records.
ABBVIE INC. accounted for 24.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Farxiga, Linzess, Mounjaro, Ozempic, Rybelsus, Trelegy Ellipta, Ubrelvy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 105 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Ubrelvy by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 87 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $307.74 | 24.6% | 6 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $226.42 | 18.1% | 6 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $183.64 | 14.7% | 3 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $148.01 | 11.8% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $130.24 | 10.4% | 6 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $64.30 | 5.1% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $57.35 | 4.6% | 3 | 2025 |
| SCILEX PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $45.49 | 3.6% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $37.96 | 3.0% | 3 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $27.56 | 2.2% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $21.67 | 1.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,250.38 | 38 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $226.42 | 6 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $157.12 | 3 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $149.55 | 3 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION | $148.01 | 4 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $104.24 | 5 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $96.97 | 5 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $64.30 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $59.25 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $57.35 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $57.35 | 3 | 2025 |
Source payment records
|
|||||
| ZTLido Normalized: ztlido |
Drug | SCILEX PHARMACEUTICALS INC. | $45.49 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $37.96 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $33.19 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $30.67 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $27.56 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $26.00 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $25.90 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $23.47 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $21.67 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 81 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 105 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 52 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 66 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
81 | 26 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
105 | 33 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
87 | 29 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
15 | 11 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
77 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
52 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
49 | 14 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
66 | 20 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 611 | 179 |
| Diclofenac Sodium | Diclofenac Sodium | 514 | 134 |
| Omeprazole | Omeprazole | 466 | 140 |
| Amlodipine Besylate | Amlodipine Besylate | 418 | 124 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 397 | 112 |
| Metformin Hcl | Metformin Hcl | 361 | 99 |
| Gabapentin | Gabapentin | 352 | 101 |
| Losartan Potassium | Losartan Potassium | 343 | 100 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 287 | 76 |
| Fluticasone Propionate | Fluticasone Propionate | 280 | 84 |
| Hydrochlorothiazide | Hydrochlorothiazide | 279 | 87 |
| Simvastatin | Simvastatin | 251 | 74 |
| Alendronate Sodium | Alendronate Sodium | 247 | 82 |
| Metoprolol Succinate | Metoprolol Succinate | 244 | 63 |
| Meclizine Hcl | Meclizine Hcl | 236 | 71 |
| Lisinopril | Lisinopril | 232 | 63 |
| Levothyroxine Sodium | Levothyroxine Sodium | 209 | 49 |
| Montelukast Sodium | Montelukast Sodium | 199 | 73 |
| Trazodone Hcl | Trazodone Hcl | 197 | 56 |
| Famotidine | Famotidine | 182 | 57 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 170 | 65 |
| Ventolin Hfa | Albuterol Sulfate | 166 | 43 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 154 | 41 |
| Azelastine Hcl | Azelastine Hcl | 153 | 40 |
| Meloxicam | Meloxicam | 148 | 48 |
| Januvia | Sitagliptin Phosphate | 143 | 30 |
| Ammonium Lactate | Ammonium Lactate | 137 | 35 |
| Vascepa | Icosapent Ethyl | 119 | 32 |
| Furosemide | Furosemide | 114 | 31 |
| Eliquis | Apixaban | 106 | 27 |
| Metoprolol Tartrate | Metoprolol Tartrate | 106 | 26 |
| Linzess | Linaclotide | 105 | 33 |
| Pantoprazole Sodium | Pantoprazole Sodium | 101 | 34 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 100 | 31 |
| Hydrocortisone | Hydrocortisone | 95 | 41 |
| Clopidogrel | Clopidogrel Bisulfate | 92 | 33 |
| Tamsulosin Hcl | Tamsulosin Hcl | 91 | 28 |
| Ibuprofen | Ibuprofen | 89 | 38 |
| Zolpidem Tartrate | Zolpidem Tartrate | 88 | 22 |
| Symbicort | Budesonide/Formoterol Fumarate | 87 | 29 |
| Enalapril Maleate | Enalapril Maleate | 84 | 24 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 83 | 24 |
| Ibuprofen-Famotidine | Ibuprofen/Famotidine | 83 | 26 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 82 | 24 |
| Creon | Lipase/Protease/Amylase | 81 | 26 |
| Metformin Er Gastric | Metformin Hcl | 80 | 22 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 79 | 37 |
| Jardiance | Empagliflozin | 77 | 20 |
| Carvedilol | Carvedilol | 75 | 23 |
| Novolog Flexpen | Insulin Aspart | 74 | 21 |
| Dexilant | Dexlansoprazole | 70 | 19 |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 70 | 20 |
| Ozempic | Semaglutide | 66 | 20 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 62 | 16 |
| Naproxen | Naproxen | 62 | 30 |
| Tradjenta | Linagliptin | 62 | 15 |
| Myrbetriq | Mirabegron | 61 | 14 |
| Tramadol Hcl | Tramadol Hcl | 57 | 29 |
| Lidocaine | Lidocaine | 56 | 13 |
| Mounjaro | Tirzepatide | 52 | 15 |
| Memantine Hcl | Memantine Hcl | 51 | 14 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 50 | 19 |
| Donepezil Hcl | Donepezil Hcl | 49 | 13 |
| Trulicity | Dulaglutide | 49 | 14 |
| Glipizide | Glipizide | 48 | 15 |
| Single Use Swab | Alcohol Antiseptic Pads | 48 | 17 |
| Glimepiride | Glimepiride | 46 | 11 |
| Chlorthalidone | Chlorthalidone | 45 | 16 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 45 | 11 |
| Nifedipine Er | Nifedipine | 44 | 14 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 44 | 15 |
| Atenolol | Atenolol | 42 | 12 |
| Repaglinide | Repaglinide | 42 | 14 |
| Desoximetasone | Desoximetasone | 41 | suppressed |
| Ezetimibe | Ezetimibe | 41 | 15 |
| Ketoconazole | Ketoconazole | 41 | 11 |
| Mirtazapine | Mirtazapine | 41 | suppressed |
| Diclofenac Sodium Er | Diclofenac Sodium | 38 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 37 | 21 |
| Glipizide Er | Glipizide | 36 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 36 | 12 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 35 | 16 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 34 | 11 |
| Finasteride | Finasteride | 34 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 34 | suppressed |
| Alcohol Swabs | Alcohol Antiseptic Pads | 33 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 33 | 25 |
| Ciclopirox | Ciclopirox | 33 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 33 | suppressed |
| Valsartan | Valsartan | 33 | 11 |
| Halobetasol Propionate | Halobetasol Propionate | 30 | suppressed |
| Levemir Flexpen | Insulin Detemir | 30 | 11 |
| Novofine 32 | Pen Needle, Diabetic | 30 | 12 |
| Tizanidine Hcl | Tizanidine Hcl | 30 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 29 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 29 | suppressed |
| Movantik | Naloxegol Oxalate | 28 | suppressed |
| Nitroglycerin | Nitroglycerin | 28 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 28 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 27 | suppressed |
| Colchicine | Colchicine | 27 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 27 | suppressed |
| Ubrelvy | Ubrogepant | 27 | suppressed |
| Azithromycin | Azithromycin | 26 | 20 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 26 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 26 | suppressed |
| Amoxicillin | Amoxicillin | 25 | 20 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 25 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 24 | suppressed |
| Folic Acid | Folic Acid | 24 | suppressed |
| Lactulose | Lactulose | 24 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 24 | suppressed |
| Premarin | Estrogens, Conjugated | 23 | suppressed |
| Rybelsus | Semaglutide | 23 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 23 | 11 |
| Xarelto | Rivaroxaban | 23 | suppressed |
| Ciclopirox | Ciclopirox Olamine | 22 | suppressed |
| Cilostazol | Cilostazol | 22 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 22 | suppressed |
| Entresto | Sacubitril/Valsartan | 22 | suppressed |
| Epinephrine | Epinephrine | 22 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 22 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 21 | suppressed |
| Brilinta | Ticagrelor | 21 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 21 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 21 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 21 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 21 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 20 | suppressed |
| Nystatin | Nystatin | 20 | suppressed |
| Spironolactone | Spironolactone | 20 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 20 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 20 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 19 | 17 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 19 | suppressed |
| Restasis | Cyclosporine | 19 | suppressed |
| Baclofen | Baclofen | 18 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 18 | suppressed |
| Fenofibrate | Fenofibrate | 18 | suppressed |
| Fluconazole | Fluconazole | 18 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 18 | suppressed |
| Levetiracetam | Levetiracetam | 18 | suppressed |
| Allopurinol | Allopurinol | 17 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 17 | 12 |
| Fenofibrate | Fenofibrate,micronized | 17 | suppressed |
| Oxiconazole Nitrate | Oxiconazole Nitrate | 17 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 16 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 16 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 16 | suppressed |
| Meloxicam | Meloxicam, Submicronized | 15 | suppressed |
| Prednisone | Prednisone | 15 | suppressed |
| Pro Comfort Alcohol Pads | Alcohol Antiseptic Pads | 15 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 15 | 11 |
| Tresiba Flextouch U-200 | Insulin Degludec | 15 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 14 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 14 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 14 | suppressed |
| Potassium Chloride | Potassium Chloride | 14 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 13 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 13 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 13 | suppressed |
| Cyclobenzaprine Hcl Er | Cyclobenzaprine Hcl | 13 | suppressed |
| Mupirocin | Mupirocin | 13 | suppressed |
| Proctozone-Hc | Hydrocortisone | 13 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 13 | suppressed |
| Topiramate | Topiramate | 13 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 12 | suppressed |
| Calcipotriene | Calcipotriene | 12 | suppressed |
| Cyclosporine | Cyclosporine | 12 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Fluocinonide | Fluocinonide | 12 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 12 | suppressed |
| Ultra-Fine Original Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 11 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 11 | suppressed |
| Diazepam | Diazepam | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Terconazole | Terconazole | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,250.38 · 38 records | ABBVIE INC. | AREXVY, BREZTRI, CREON, DUPIXENT, FARXIGA, LINZESS, MOUNJARO, OTEZLA, Ozempic, QULIPTA, REPATHA, Rybelsus, TRELEGY ELLIPTA, UBRELVY, VOQUEZNA, XIFAXAN, ZEPBOUND, ZORYVE, ZTLido | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error